Literature DB >> 11286556

Conformational properties of alpha-synuclein in its free and lipid-associated states.

D Eliezer1, E Kutluay, R Bussell, G Browne.   

Abstract

alpha-Synuclein (alphaS) is a presynaptic terminal protein that is believed to play an important role in the pathogenesis of Parkinson's disease (PD). We have used NMR spectroscopy to characterize the conformational properties of alphaS in solution as a free monomer and when bound to lipid vesicles and lipid-mimetic detergent micelles. Free wild-type alphaS is largely unfolded in solution, but exhibits a region with a preference for helical conformations that may be important in the aggregation of alphaS into fibrils. The N-terminal region of alphaS binds to synthetic lipid vesicles and detergent micelles in vitro and adopts a highly helical conformation, consistent with predictions based on sequence analysis. The C-terminal part of the protein does not associate with either vesicles or micelles, remaining free and unfolded. These results suggest that one function of alphaS may be to tether as of yet unidentified partners to lipid surfaces via interactions with its C-terminal tail. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11286556     DOI: 10.1006/jmbi.2001.4538

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  396 in total

1.  The N-terminus of the intrinsically disordered protein α-synuclein triggers membrane binding and helix folding.

Authors:  Tim Bartels; Logan S Ahlstrom; Avigdor Leftin; Frits Kamp; Christian Haass; Michael F Brown; Klaus Beyer
Journal:  Biophys J       Date:  2010-10-06       Impact factor: 4.033

2.  Effects of curvature and composition on α-synuclein binding to lipid vesicles.

Authors:  Elizabeth R Middleton; Elizabeth Rhoades
Journal:  Biophys J       Date:  2010-10-06       Impact factor: 4.033

3.  N-Terminal acetylation is critical for forming α-helical oligomer of α-synuclein.

Authors:  Adam J Trexler; Elizabeth Rhoades
Journal:  Protein Sci       Date:  2012-03-30       Impact factor: 6.725

4.  Polycation-induced oligomerization and accelerated fibrillation of human alpha-synuclein in vitro.

Authors:  John Goers; Vladimir N Uversky; Anthony L Fink
Journal:  Protein Sci       Date:  2003-04       Impact factor: 6.725

5.  Structure of membrane-bound alpha-synuclein studied by site-directed spin labeling.

Authors:  Christine C Jao; Ani Der-Sarkissian; Jeannie Chen; Ralf Langen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-20       Impact factor: 11.205

6.  Lipid rafts mediate the synaptic localization of alpha-synuclein.

Authors:  Doris L Fortin; Matthew D Troyer; Ken Nakamura; Shin-ichiro Kubo; Malcolm D Anthony; Robert H Edwards
Journal:  J Neurosci       Date:  2004-07-28       Impact factor: 6.167

7.  Effects of small-molecule amyloid modulators on a Drosophila model of Parkinson's disease.

Authors:  Małgorzata Pokrzywa; Katarzyna Pawełek; Weronika Elżbieta Kucia; Szymon Sarbak; Erik Chorell; Fredrik Almqvist; Pernilla Wittung-Stafshede
Journal:  PLoS One       Date:  2017-09-01       Impact factor: 3.240

8.  Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL).

Authors:  Cristian Follmer; Eduardo Coelho-Cerqueira; Danilo Y Yatabe-Franco; Gabriel D T Araujo; Anderson S Pinheiro; Gilberto B Domont; David Eliezer
Journal:  J Biol Chem       Date:  2015-09-17       Impact factor: 5.157

9.  Helix periodicity, topology, and dynamics of membrane-associated alpha-synuclein.

Authors:  Robert Bussell; Trudy Fiona Ramlall; David Eliezer
Journal:  Protein Sci       Date:  2005-03-01       Impact factor: 6.725

10.  Quantification of alpha-synuclein binding to lipid vesicles using fluorescence correlation spectroscopy.

Authors:  Elizabeth Rhoades; Trudy F Ramlall; Watt W Webb; David Eliezer
Journal:  Biophys J       Date:  2006-03-31       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.